Use of Wharton Jelly in Diabetic Nephropathy

Inclusion Criteria: * Willing and able to provide written informed consent. * Type 2 diabetes mellitus (DM) for ≥ 3 years. * Estimated GFR (eGFR) 15-45 ml/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation on 2 or more consecutive measurements at least 30 days apart within the past 6 months, confirmed by isotope kidney scan. * Urine protein-to-creatinine ratio (UPCR) ≥ 500 mg/mmol (in spot urine or in 24 hour urine collection) confirmed twice over a period of 6 months. * Ultrasonographic kidney measurements ≥ 10 cm (for both kidneys). Exclusion Criteria: * Patients with uncontrolled hyper or hypo tension; (systolic pressure \>160, \<100: diastolic pressure \< 60, \>100) on two different occasions. * Poor diabetic control: Hemoglobin A1c (HbA1c) \> 10%. * New use of hypoglycemic, antihypertensive and/or lipid lowering agent within the past 6 months. * Increase in the dose of anti-hypertensive and/or hypoglycemic agent of the previous dose within the past 3 months. * Current fasting total cholesterol \>300 mg/dl. * Current fasting total triglycerides \>400 mg/dl. * History of any cardiovascular events in the past 6 months. * Pregnancy or lactating. * Positive screening test for infectious diseases as per baseline work up. * History of kidney transplant * Systemic autoimmune disease. * Receiving immunosuppressant medications. * Patients with glomerulonephritis or any non-DM related kidney disease. * Patients with any coagulation disorder.